Reliable MRSA Screening for Hospitals and Laboratories in less than 2 hours
Methicillin-resistant Staphylococcus aureus (MRSA) is one of the most dreaded causes of nosocomial infections in hospitals and other public health institutions, resulting in hospital-acquired MRSA or HA-MRSA. The bacteria can enter the body through a wound or medical intervention and cause wound infection, lung inflammation and sepsis. Because of the resistance to antibiotics, MRSA infections are very difficult to treat and can be potentially fatal. The prevalence of MRSA infection within Europe varies greatly. Infection rates range from 1% in northern Europe to over 25% in southern Europe. Germany had an MRSA infection rate of 20.9% in 2010.1
Proportion of invasive Staphylococcus aureus isolates resistant to oxacillin/methicillin in 2010.1
Every MRSA infection can cause hospital costs, up to € 10.000.2 MRSA infections affect more than 150.000 hospitalized patients in the European Union, resulting in attributable extra costs of € 380 million for the European healthcare system each year.3 An early, rapid and systematic MRSA screening can significantly reduce the rate of MRSA infection, its transmission and the associated costs.
Real-time polymerase chain reaction (PCR) assays enable an early and rapid MRSA screening on the same day of hospital admission as part of an infection prevention program („search and destroy“ strategy).
R-Biopharm AG offers RIDA®GENE MRSA, a multiplex real-time PCR system for the specific detection of MRSA from nasal swabs and culture samples, providing test results in less than 2 hours. Unlike single-locus PCRs, RIDA®GENE MRSA minimizes false-positive results due to the separate detection of the SCCmec/orfX junction, the mecA gene and the orfX gene (S. aureus). The RIDA®GENE MRSA real-time PCR contains all components needed for rapid assay performance, including lysis buffer.
Advantages of RIDA®GENE MRSA:
- Direct detection of MRSA from nasal swabs and culture samples
- Results in less than 2 hours
- Separate detection of the SCCmec/orfX junction, the mecA gene and the orfX gene (S. aureus) minimizes the number of false-positive results
- Flexible – can be run on the commonly used real-time PCR instruments:
1. ECDC 2011: Antimicrobial resistence surveillance in Europe 2010.
2. Diller R, et al. Int J Hyg Environ Health 2008; 211 (1-2): 205-212.
3. Köck R, et al. Euro Surveill. 2010; 15 (41):19688.